Glipizide
As of the edition of 20 October 2026, Glipizide is a small molecule: marketed, first approved in 1973 (ES); acts on ABCC8 and KCNJ11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1984
- Kind
- Small molecule
- Brand name
- Glucotrol
- First approved
- 1 June 1973 (ES)
- Approvals on record
- 10 in 2 regions
- Holder of the most recent approval
- Bristol Myers Squibb; 2 holders in all
- Registered trials
- 16, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Cancer; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1984 to now |